We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison) (LIAISON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01567280
Recruitment Status : Completed
First Posted : March 30, 2012
Last Update Posted : January 21, 2015
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Brief Summary:

The study design consists of a cross-sectional survey on the clinical characteristics of patients with asthma and their level of asthma control and current quality of life, and on a prospective evaluation of the rate of switch from the uncontrolled/poorly controlled condition to the status of controlled asthma. Asthma control will be based on the Asthma Control Questionnaire scoring system, that has been fully validated for use in both clinical practice and clinical trials and has strong discriminative properties which means that it can detect small differences between patients with different levels of asthma control and it is very sensitive to within-patient change in asthma control over time.

Quality of life as a reflection of the control of the disease, will also be evaluated by means of the Mini Asthma Quality of Life Questionnaire scoring system.

Condition or disease

Study Type : Observational
Actual Enrollment : 8111 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)
Study Start Date : May 2012
Primary Completion Date : October 2013
Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Controlled patients
Asthmatic patients with controlled asthma (according to ACQ score)
Partly controlled/Uncontrolled patients
Patients with partly controlled or uncontrolled asthma (according to ACQ score)

Primary Outcome Measures :
  1. Asthma Control Questionnaire score [ Time Frame: 3 months ]
  2. Mini Asthma Quality of Life Questionnaire score [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Asthmatic patients (in treatment with the same antiasthmatic therapy for at least 4 weeks) visiting the centre.

Inclusion Criteria:

  • Inclusion criteria:

    1. Written informed consent obtained.
    2. Male or female adult (at least 18 years of age) patients with asthma diagnosed (according to GINA guidelines and confirmed by a chest physician) for at least 6 months.
    3. Patients in treatment with the same antiasthmatic drugs in the last 4 weeks before enrolment.
  • Exclusion criteria:

    1. Patients enrolled in clinical trial in the previous 4 weeks or subjects already admitted in this study.
    2. Patients suffering from conditions and illnesses that might interfere with the study purpose, according to the investigator's evaluation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01567280

Azienda Sanitaria Firenze Piero Palagi
Firenze, Italy, 50125
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier: NCT01567280     History of Changes
Other Study ID Numbers: DFIDM-1101
First Posted: March 30, 2012    Key Record Dates
Last Update Posted: January 21, 2015
Last Verified: January 2015

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases